anti-MCL-1 program Cell Penetrating Alphabodies (Complix)

N/A

Report date: 2025/01/26 19:13:13

Base Information

Drug Nameanti-MCL-1 program Cell Penetrating Alphabodies (Complix)
Drug Alias Namealphabody-based therapy (Complix)CMPX-321A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsInduced myeloid leukemia cell differentiation protein Mcl-1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesComplix NV
China Registration ClassN/A

Develop Information

Active CompaniesComplix NV
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A